Literature DB >> 29192374

Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study.

Ki Tae Suk1, Moon Young Kim2, Soung Won Jeong3, Jae Young Jang3, Yoon Ok Jang4, Soon Koo Baik5,6,7.   

Abstract

BACKGROUND/AIMS: Hepatopulmonary syndrome (HPS) is characterized by a defect in oxygenation induced by pulmonary vascular dilatation in cirrhosis. While severe HPS is responsible for a high rate of mortality, the prevalence and pathophysiology of HPS are not fully elucidated. We evaluated the prevalence and pathophysiology of HPS in patients with cirrhosis.
METHODS: A total of 142 patients with cirrhosis who underwent saline-agitated contrast echocardiography were enrolled in this prospective observational study. HPS was defined by positive findings on contrast echocardiography, cirrhosis, and the presence of an oxygenation defect (alveolar-arterial oxygen gradient > 15 mmHg). HPS grades from 0 to 3 were assigned based on the density and spatial distribution of microbubbles in the left ventricle. The primary endpoint was the prevalence of HPS. The secondary endpoints included clinical characteristics and levels of lipopolysaccharide (LPS), LPS-binding protein (LBP), nitric oxide, and endothelin-1 in HPS.
RESULTS: Fifty-nine patients (41.5%) were diagnosed with HPS (grade 1: 24, grade 2: 23, and grade 3: 12 patients). The mean levels of LPS (0.36 ± 0.02, 1.02 ± 0.18, 2.86 ± 0.77, and 6.56 ± 1.46 EU/mL, p < 0.001) and LBP (7026 ± 3336, 11,445 ± 1247, 11,947 ± 1164, and 13,791 ± 2032 ng/mL, p = 0.045) were found to be increased according to HPS grade (negative, grade 1-3). Endothelin-1 levels were significantly elevated according to HPS grade (1.83 ± 0.17, 2.62 ± 0.22, 3.69 ± 0.28, and 4.29 ± 0.34 pg/mL, p < 0.001), demonstrating a significant difference between each grade (p < 0.05).
CONCLUSIONS: HPS is a common complication with a prevalence of 41.5% in patients with cirrhosis. Bacterial translocation and portal pulmonary vascular dilatation are key mechanism involved in the progression of HPS.

Entities:  

Keywords:  Bacterial translocation; Cirrhosis; Hepatopulmonary syndrome; Lipopolysaccharide

Mesh:

Year:  2017        PMID: 29192374     DOI: 10.1007/s10620-017-4868-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  43 in total

1.  Exercise-induced intrapulmonary arteriovenous shunting and pulmonary gas exchange.

Authors:  Michael K Stickland; Andrew T Lovering
Journal:  Exerc Sport Sci Rev       Date:  2006-07       Impact factor: 6.230

Review 2.  Mediators, cytokines, and growth factors in liver-lung interactions.

Authors:  R J Panos; S K Baker
Journal:  Clin Chest Med       Date:  1996-03       Impact factor: 2.878

Review 3.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

4.  Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue.

Authors:  M J Krowka; E R Dickson; D A Cortese
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

5.  N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome.

Authors:  Rafael Vercelino; Juliana Tieppo; Alexandre Simões Dias; Cláudio Augusto Marroni; Eduardo Garcia; Luise Meurer; Jaqueline Nascimento Picada; Norma Possa Marroni
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-04       Impact factor: 4.080

6.  Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial.

Authors:  Ki Tae Suk; Jung-Hwan Yoon; Moon Young Kim; Chang Wook Kim; Ja Kyung Kim; Hana Park; Seong Gyu Hwang; Dong Joon Kim; Byung Seok Lee; Sae Hwan Lee; Hong Soo Kim; Jae Young Jang; Chang-Hyeong Lee; Byung Seok Kim; Yoon Ok Jang; Mee Yon Cho; Eun Sun Jung; Yong Man Kim; Si Hyun Bae; Soon Koo Baik
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

7.  Prevalence of hepatopulmonary syndrome in children.

Authors:  Khalid Noli; Melinda Solomon; Fraser Golding; Martin Charron; Simon C Ling
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

8.  Improved severe hepatopulmonary syndrome after liver transplantation in an adolescent with end-stage liver disease secondary to biliary atresia.

Authors:  Tae Jun Park; Keun Soo Ahn; Yong Hoon Kim; Hyungseop Kim; Ui Jun Park; Hyoung Tae Kim; Won Hyun Cho; Woo-Hyun Park; Koo Jeong Kang
Journal:  Clin Mol Hepatol       Date:  2014-03-26

Review 9.  Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Gaeun Kim; Kwang Yong Shim; Soon Koo Baik
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

Review 10.  Acute kidney injury in liver cirrhosis: new definition and application.

Authors:  Florence Wong
Journal:  Clin Mol Hepatol       Date:  2016-12-14
View more
  2 in total

1.  Hepatocyte-derived exosomal MiR-194 activates PMVECs and promotes angiogenesis in hepatopulmonary syndrome.

Authors:  Lin Chen; Yi Han; Yujie Li; Bing Chen; Xuehong Bai; Karine Belguise; Xiaobo Wang; Yang Chen; Bin Yi; Kaizhi Lu
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

2.  Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study.

Authors:  Nuria Mendoza; Eva Rivas; Roberto Rodriguez-Roisin; Tamara Garcia; Miquel Bruguera; Alvar Agusti; Rosa Faner
Journal:  PLoS One       Date:  2021-02-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.